中文 | English
Return
Total: 11 , 1/2
Show Home Prev Next End page: GO
Author:(Chunlin ZHUANG)

1."Application of self-made blood""sampling-taking-transfusion""simulation video in management of ;safe blood transfusion"

Shouying LV ; Ailing LIU ; Guangyun ZHUANG ; Chunlin YAN

Chinese Journal of Practical Nursing 2016;32(32):2525-2528

2.Research progress on the chemicals with cancer stem cell growth inhibitory activity

Jiao LI ; Hua TANG ; Chunlin ZHUANG ; Peng SUN ; Fujia MA ; Wen ZHANG

Chinese Journal of Biochemical Pharmaceutics 2017;37(3):20-26

3.Methodology of drug screening and target identification for new necroptosis inhibitors

Pengchao PAN ; Zhenyu CAI ; Chunlin ZHUANG ; Xiaofei CHEN ; Yifeng CHAI

Journal of Pharmaceutical Analysis 2019;9(2):71-76

4.Recent research progress on anti-microtubule agents targeting multi-drug resistant cancers

Saijian SHI ; Wen ZHANG ; Tingyou LI ; Chunlin ZHUANG

Journal of Pharmaceutical Practice 2017;35(5):385-393,397

5.Study on chemical constitunts of sponge Agelas mauritiana from the South China Sea

Fengkai FANG ; Hua TANG ; Baoshu LIU ; Chunlin ZHUANG ; Peng SUN ; Wen ZHANG

Journal of Pharmaceutical Practice 2015;(3):242-245,274

6.Research progress on small molecule inhibitors of coronaviruses

Zhengguang YAO ; Zhibin WANG ; Chunnian XIA ; Chunlin ZHUANG

Journal of Pharmaceutical Practice 2020;38(5):385-397

7.Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years.

Chunlin ZHUANG ; Christophe PANNECOUQUE ; Erik DE CLERCQ ; Fener CHEN

Acta Pharmaceutica Sinica B 2020;10(6):961-978

8.Cytotoxicity study on FC58, an indole-chalcone, against multi-drug resistant leukemia cells

Jiawei DAI ; Saijian SHI ; Aiwei SONG ; Zhibin WANG ; Chunlin ZHUANG ; Chunnian XIA

Journal of Pharmaceutical Practice 2021;39(4):305-308

9.Research progresses on the main active components in Ningxia Sophora alopecuroides and the therapeutic activities for liver diseases

Danni QUAN ; Yue XU ; Zhuo QU ; Weiheng XU ; Wannian ZHANG ; Chunlin ZHUANG

Journal of Pharmaceutical Practice 2022;40(1):1-5

10.Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy.

Jing ZHU ; Meng XIN ; Congcong XU ; Yuan HE ; Wannian ZHANG ; Zhibin WANG ; Chunlin ZHUANG

Acta Pharmaceutica Sinica B 2021;11(10):3193-3205

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 11 , 1/2 Show Home Prev Next End page: GO